<mark id="kfdvi"></mark>

<small id="kfdvi"><menu id="kfdvi"></menu></small>
    1. <small id="kfdvi"></small>

      Breadcrumb navigation

      NEC's Drug Discovery Business

      We utilize a broad range of IT and AI technologies in various drug discovery activities.

      NEC develops cancer vaccines using AI technologies.

      Partner & Pipeline

      Target Indication: Liver cancer, Gastrointestinal cancer
      A spin-off company of NEC that was established in 2016. Its peptide vaccine drug was identified by NEC's AI and clinical trials have been initiated.
      Target Indication: Ovarian cancer, Head and neck cancer
      Transgene and NEC to start clinical development of lead myvac™ individualized immunotherapy, TG4050, in 2019. This collaboration harnesses Transgene’s myvac™ platform and NEC’s long-standing Artificial Intelligence capabilities to develop an individualised neoantigen cancer vaccine.
      NEC has made a Series A strategic investment in BostonGene, a pioneer in the use of biomedical software for advanced patient analysis. BostonGene has discovered, developed, and patented a holistic approach to cancer treatment by defining the optimal therapy combination for individual patients, with a particular focus on immuno and targeted therapies.
      Parker Institute for Cancer Immunotherapy
      NEC becomes the first Japanese company to join the Parker Institute for Cancer Immunotherapy’s international TESLA consortium. This global bioinformatics collaborative includes scientists from more than 35 of the leading neoantigen research groups in academia, nonprofit and industry. The goal is to find the most effective ways to use algorithms for predicting which cancer neoantigens encoded in DNA and RNA can be recognized by and stimulate an immune response.

      Press release